Affordable Access

Publisher Website

Some Considerations About Cardiac Toxicity of Combination Therapy for Chronic Hepatitis C

Authors
Journal
Hepatitis Monthly
1735-143X
Publisher
Kowsar Medical Institute
Publication Date
Volume
13
Issue
5
Identifiers
DOI: 10.5812/hepatmon.8962
Keywords
  • Letter
Disciplines
  • Medicine

Abstract

Some Considerations About Cardiac Toxicity of Combination Therapy for Chronic Hepatitis C Reza Karbasi-Afshar 1 , Amin Saburi 2, 3, * 1 Cardiovascular Diseases Department, Baqiyatallah University of Medical Sciences, Tehran, IR Iran 2 Chemical Injuries Research Center, Baqiyatallah University of Medical Sciences, Tehran, IR Iran 3 Baqiyatallah Research Center of Gastroenterology and Liver Diseases (BRCGL), Baqiyatallah University of Medical Sciences, Tehran, IR Iran *Corresponding author: Amin Saburi, Chemical Injuries Research Center and Baqiyatallah Research Center of Gastroenterology and Liver diseases (BRCGL), Baqiyatallah University of Medical Sciences, Mollasadra St, Vanak Sq, Tehran, IR Iran. Tel/Fax: +98-2188600067, E-mail: [email protected], saburi@ brcgl.com. Keywords: Hepatitis C; Interferon-Gamma; Ribavirin; Combined Modality Therapy Article type: Letter; Received: 05 Nov 2012; Accepted: 17 Dec 2012; Epub: 14 May 2013 Please cite this paper as: Karbasi-Afshar R, Saburi A. Some Considerations About Cardiac Toxicity of Combination Therapy for Chronic Hepatitis C. Hepat Mon. 2013;13(5):e8962. DOI: 10.5812/hepatmon.8962 Copyright © 2013, Kowsar Corp.; Published by Kowsar Corp. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which per- mits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Dear Editor, We read with great interest the recently published arti- cle by Almawardy et al entitled “Is Combination Therapy for Chronic Hepatitis C Toxic for Cardiac Function?” (1). They skillfully evaluated 120 cases with hepatitis C virus infections treated with a combination protocol consist- ing interferon gamma (INFg) a or b in addition to Riba- virin and their aimed to evaluate cardiac toxicity of this regiment during six months treatment. They finally con- cluded that “combination therapy does n

There are no comments yet on this publication. Be the first to share your thoughts.